UBS analyst Danielle Antalffy lowered the firm’s price target on DexCom to $138 from $175 and keeps a Buy rating on the shares. Current multiples seem to be pricing in an overly bearish view, in which TAMs are cut meaningfully as GLP-1 adoption ramps, specifically in diabetes and obstructive sleep apnea, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DXCM:
- Early notable gainers among liquid option names on August 30th
- Jefferies healthcare analyst holds an analyst/industry conference call
- DexCom put volume heavy and directionally bearish
- 3 Best Stocks to Buy Now, 8/21/2023, According to Top Analysts
- DexCom price target lowered to $130 from $153 at Baird